Apixaban: Phase III data

In the double-blind, international Phase III ADVANCE-2 trial in 1,973 patients, apixaban was superior to Lovenox enoxaparin on the composite primary endpoint of asymptomatic and symptomatic DVT, non-fatal PE and death by any cause at 12 days (15% vs. 24%, p<0.0001). There was no significant difference in the rates of major bleeding (0.6% vs. 0.9%, p=0.3) or composite major or clinically relevant non-major bleeding (4% vs. 5%, p=0.09) between apixaban and Lovenox. Patients undergoing total knee replacement surgery received 2.5 mg twice-daily oral apixaban started 12-24 hours after surgery or 40 mg once-daily subcutaneous Lovenox started 12 hours before surgery and resumed an average of 19 hours after surgery. Data were published in The Lancet. ...